DOCSLIB.ORG

A New Method for the Detection of Pneumocystis Jirovecii Using Flow Cytometry

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A New Method for the Detection of Pneumocystis Jirovecii Using Flow Cytometry Eur J Clin Microbiol Infect Dis (2010) 29:1147–1152 DOI 10.1007/s10096-010-0980-5 ARTICLE A new method for the detection of Pneumocystis jirovecii using flow cytometry J. Barbosa & C. Bragada & S. Costa-de-Oliveira & E. Ricardo & A. G. Rodrigues & C. Pina-Vaz Received: 7 August 2009 /Accepted: 22 May 2010 /Published online: 16 June 2010 # Springer-Verlag 2010 Abstract Pneumocystis jirovecii is an opportunistic patho- reactions to bacteria or fungi. All positive cases detected by gen responsible for severe pneumonia in immunocompro- IFS were positive by FC; however, FC classified eight mised patients. Its diagnosis has been based upon direct samples to be positive which were classified as negative by microscopy either by classic staining (Gomori Grocott) or routine technique. These samples were obtained from by epifluorescence microscopy (immunofluorescence stain- patients with respiratory symptoms who responded favour- ing, IFS), both of which are time-consuming and low on ably to Pneumocystis-specific therapy and were subsequently sensitivity. Our aim was to develop a flow cytometric (FC) considered to be true-positives. Using clinical diagnosis as a protocol for the detection of P. jirovecii on respiratory reference method, FC showed 100% sensitivity and speci- samples. In our study, 420 respiratory samples were analysed ficity, whereas IFS showed 90.9% sensitivity and 100% in parallel by IFS and FC, and compared from clinical specificity. According to our results, a new diagnostic diagnosis to its resolution upon specific anti-Pneumocystis approach is now available to detect P. jirovecii in respiratory therapy. The optimum specific antibody concentration for FC samples. analysis was determined to be 10 µg/ml, without any cross- Introduction * : : : : J. Barbosa ( ) :C. Bragada S. Costa-de-Oliveira E. Ricardo A. G. Rodrigues C. Pina-Vaz Pneumocystis jirovecii (previously named Pneumocystis Department of Microbiology, Porto Faculty of Medicine, carinii University of Porto, ) is an atypical fungus. For 80 years, it was Al. Prof. Hernâni Monteiro, considered to be a protozoan, since its diagnostic form is 4200-319 Porto, Portugal a cyst, but ribosomal RNA and DNA studies demonstrated e-mail: [email protected] similarities to fungus [1]. In 2001, this microorganism was J. Barbosa officially reclassified as a fungus belonging to the class Escola Superior de Saúde Jean Piaget, Archiascomycetes [1] and was renamed P. jirovecii [2]. In Vila Nova de Gaia, Portugal humans, this pathogen is responsible for an opportunistic infection at the lower respiratory tract, but it can lead to A. G. Rodrigues Pneumocystis Burn Unit, Department of Plastic and Reconstructive Surgery, severe pneumonia (PcP) in immunocompro- Hospital S. João, mised patients, particularly in those with AIDS [3, 4]. Prior Porto, Portugal to the AIDS epidemic, P. jirovecii had been sporadically reported as a cause of death in malnourished infants and C. Pina-Vaz Department of Microbiology, Hospital S. João, responsible for epidemics in institutions like nursing homes Porto, Portugal and hospitals [5]. Currently, it represents the most frequent : : : AIDS opportunistic pathogen, although PcP incidence has S. Costa-de-Oliveira E. Ricardo A. G. Rodrigues C. Pina-Vaz decreased significantly due to the extensive use of highly Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, active anti-retroviral therapy (HAART) and prophylactic Porto, Portugal treatment [4–6]. PcP may also represent a small fraction of 1148 Eur J Clin Microbiol Infect Dis (2010) 29:1147–1152 respiratory infections in patients with pulmonary diseases patients, 130 were HIV-positive. Samples were kindly such as chronic obstructive pulmonary disease (COPD) or provided by the Microbiology Laboratories of several displaying immunity conditions like malignancy [7, 8]. Portuguese hospitals, namely, Hospital São João (HSJ, Porto, Over the past 15 years, P. jirovecii carriage in healthy Portugal), Instituto Português de Oncologia Francisco Gentil subjects has been widely demonstrated through the pres- (IPOFG, Porto, Portugal), Hospital Joaquim Urbano (HJU, ence of anti-P. jirovecii antibodies in their serum, with Porto, Portugal) and Centro Hospitalar de Coimbra (CHC, serologic analysis being used simply for the assessment of Coimbra, Portugal). A maximum of 30 mL of BAL or BW, the infection epidemiology [9]. PcP, however, is considered and 2 to 4 mL of BS samples were placed in a sterile container to result from de novo infection rather than from the and frozen at −70°C for further processing for immunofluo- reactivation of a latent infection [6]. It is assumed that rescence staining (IFS) and FC analysis. human transmission of P. jirovecii occurs through the airborne route, as suggested by studies performed in rodent Sample preparation models [6]. Nonetheless, inter-individual transmission has been suggested due to the occurrence of PcP case clusters For IFS, clinical samples were mixed with mucolytic agent in hospitals, namely, in paediatrics, hematology–oncology, N-acetyl-L-cysteine (Merck®) and incubated in a water intensive care, transplantation unit and infectious diseases bath at 37°C for 20 min or until complete dissolution, units [10]. P. jirovecii may be exhaled to the environment followed by centrifugation at 3,000g for 15 min. Subse- from infected patients, as demonstrated from cyst DNA quently, the samples were washed twice with sterile water detection in air filters from the hospital rooms of patients (H2O), centrifuged as above and the sediment re-suspended who developed PcP [10]. in a small volume of water which was divided into two The detection of P. jirovecii in an infected patient is portions; one portion was placed on a glass slide, air dried based upon the direct visualisation of organisms (cysts, and fixed, while the other portion was used for FC analysis. sporocysts or trophozoites) in clinical specimens, such as bronchoalveolar lavage (BAL), induced sputum (IS) or lung Immunofluorescence staining biopsy, which is the gold-standard specimen [6, 11]. Although specific fluorescent staining techniques were Smears were stained according to the manufacturer’sinstruc- developed for assessment under fluorescent microscopy, tions with the Detect IF™ kit Pneumocystis carinii such methods are very time-consuming, too cumbersome (Axis-Shield Diagnostics Limited, United Kingdom) and and subject to human error, especially when samples yield a analysed under an epifluorescence microscope Leitz Labor- low number of P. jirovecii organisms [11]. Molecular lux K (Leica, NY, USA). Smears were considered to be studies such as polymerase chain reaction (PCR) presented positive for P. jirovecii whenever two or more green cysts a higher sensitivity and variable specificity when compared were visualised, whether isolated or in a group. to the microscopic detection of P. jirovecii in BAL [12, 13]. However, PCR remains unavailable in most clinical Optimisation of a flow cytometry protocol microbiology laboratories and is an expensive technique [14, 15]. More so, a variable specificity has been described For the optimisation of the FC protocol, a mix of four ranging from 62.5 to 100%, depending on the type of positive samples and a mix of four negative samples specimen [14, 15]. Distinct applications of flow cytometry (evaluated by IFS) were prepared. Samples were divided (FC) in microbiology have been developed by our group in into two equal aliquots and one of them was passed through order to increase the diagnostic sensitivity in clinical a filter with a 30-μm pore size (Partec CellTrics®). Twenty samples [16–18]. In the present study, we have developed microlitres of specific enzyme from Detect IF™ kit and optimised a specific FC protocol for the detection of P. Pneumocystis carinii (Axis-Shield Diagnostics Limited, jirovecii on respiratory samples. United Kingdom) were added to 100 µl of the respiratory sample and incubated at 37°C for 30 min; 500 µl of sterile H2O were then added and a subsequent centrifugation was Materials and methods performed at 3,000g for 5 min. One hundred microlitres of centrifuged sample were Clinical specimens stained with serial concentrations (0, 5.0, 10.0, 15.0 and 20.0 μl) of specific P. jirovecii mouse monoclonal antibody A total of 420 samples, including 380 BAL and bronchial (Axis-Shield Diagnostics Limited, United Kingdom), washing (BW) specimens, and 40 bronchial secretion (BS) followed by dark incubation at 37°C for 15 min. Subse- aspirates, were prospectively collected from patients with quently, 500 µl of sterile H2O were added and centrifuga- different immunological conditions. From those 420 tion at 3,000g for 5 min was performed; the supernatant Eur J Clin Microbiol Infect Dis (2010) 29:1147–1152 1149 was discarded and the pellet re-suspended in 100 μlof Data comparison sterile H2O, vortexed for 30 s, transferred to a propylene tube and analysed by FC. The results of IFS were compared to those obtained by FC. Clinical diagnosis was used as the standard. When results Flow cytometry analysis were discrepant, clinical symptoms and signs were consid- ered; patients with oxygen level PaO2 <70 mmHg, an X-ray The optical characteristics of the cysts suspensions were depicting a diffuse bilateral infiltrate and with a favourable evaluated on a FACSCalibur flow cytometer (BD Bioscien- outcome upon specific therapy were considered as true- ces, Sydney , Australia) standard model equipped with three positive cases for PcP. photomultipliers (PMTs), standard filters (FL1: BP 530/30 nm; FL2: BP 585/42 nm; FL3: LP 650 nm), a 15-mW 488-nm argon laser and with CellQuest Pro Software Results (version 4.0.2, BD Biosciences, Sydney, Australia). Operating conditions included log scales on all detectors (forward scatter Respiratory samples were considered to be positive for P. [FSC], side scatter [SSC] and fluorescence detectors [FL1]). jirovecii when two or more green round formations, Acquisition settings were defined using a non-stained sample namely, cysts, were observed on epifluorescence micros- (autofluorescence) and adjusting the PMTs’ voltage to the first copy. By IFS, 340 samples were negative and 80 samples logarithmic (log) decade.
Load more

Recommended publications
  • Obligate Biotrophs of Humans and Other Mammals
    Pearls Genomic Insights into the Fungal Pathogens of the Genus Pneumocystis: Obligate Biotrophs of Humans and Other Mammals Philippe M. Hauser* Institute of Microbiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland Pneumocystis organisms were first believed to be a single telomeres were not assembled. The nuclear genomes of the three protozoan species able to colonize the lungs of all mammals. Pneumocystis spp. are approximately 8 Mb. Subsequently, genetic analyses revealed their affiliation to the The mitochondrial genomes of P. murina and P. carinii are fungal Taphrinomycotina subphylum of the Ascomycota, a clade approximately 25 kb, whereas that of P. jirovecii is around 35 kb which encompasses plant pathogens and free-living yeasts. It also (Table 1). This size difference is due to a supplementary region that is appeared that, despite their similar morphological appearance, non-coding and highly variable in size and sequence among isolates these fungi constitute a family of relatively divergent species, each [5]. The circular structure of the P. jirovecii mitochondrial genome with a strict specificity for a unique mammalian species [1]. The differs from the linear one present in the two other Pneumocystis spp. species colonizing human lungs, Pneumocystis jirovecii, can turn The biological significance of this difference remains unknown. into an opportunistic pathogen that causes Pneumocystis pneu- monia (PCP) in immunocompromised individuals, a disease which Genome Content may be fatal. Although the incidence of PCP diminished in the 1990s thanks to prophylaxis and antiretroviral therapy, PCP is Using gene models specifically developed, the three Pneumo- nowadays the second-most-frequent, life-threatening, invasive cystis spp.
    [Show full text]
  • 1. Economic, Ecological and Cultural Importance of Fungi
    1. Economic, ecological and cultural importance of Fungi Fungi as food Yeast fermentations, Saccaromyces cerevesiae [Ascomycota] alcoholic beverages, yeast leavened bread Glucose 2 glyceraldehyde-3-phosphate + 2 ATP 2 NAD O2 2 NADH2 2 pyruvate + 2 ATP + 2 H2O 2 ethanol 2 acetaldehyde + 2 ATP + 2 CO2 Fungi as food Citric acid Aspergillus niger Fungi as food Cheese Penicillium camembertii, Penicillium roquefortii Rennet, chymosin produced by Rhizomucor miehei and recombinant Aspergillus niger, Saccharomyces cerevesiae chymosin first GM enzyme approved for use in food Fungi as food Quorn mycoprotein, produced from biomass of Fusarium venenatum [Ascomycota] Fungi as food Red yeast rice, Monascus purpureus Soy fermentations, Aspergillus oryzae [Ascomycota] contains lovastatin? Tempeh, made with Rhizopus oligosporus [Zygomycota] Fungi as food Other fungal food products: vitamins and enzymes • vitamins: riboflavin (vitamin B2), commercially produced by Ashbya gossypii • chocolate: cacao beans fermented before being made into chocolate with a mixture of yeasts and filamentous fungi: Candida krusei, Geotrichum candidum, Hansenula anomala, Pichia fermentans • candy: invertase, commercially produced by Aspergillus niger, various yeasts, enzyme splits disaccharide sucrose into glucose and fructose, used to make candy with soft centers • glucoamylase: Aspergillus niger, used in baking to increase fermentable sugar, also a cause of “baker’s asthma” • pectinases, proteases, glucanases for clarifying juices, beverages Fungi as food Perigord truffle, Tuber
    [Show full text]
  • Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments
    pathogens Review Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments Aaron D. Gingerich 1,2, Karen A. Norris 1,2 and Jarrod J. Mousa 1,2,* 1 Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA; [email protected] (A.D.G.); [email protected] (K.A.N.) 2 Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA * Correspondence: [email protected] Abstract: For individuals who are immunocompromised, the opportunistic fungal pathogen Pneumocystis jirovecii is capable of causing life-threatening pneumonia as the causative agent of Pneumocystis pneumonia (PCP). PCP remains an acquired immunodeficiency disease (AIDS)-defining illness in the era of antiretroviral therapy. In addition, a rise in non-human immunodeficiency virus (HIV)-associated PCP has been observed due to increased usage of immunosuppressive and im- munomodulating therapies. With the persistence of HIV-related PCP cases and associated morbidity and mortality, as well as difficult to diagnose non-HIV-related PCP cases, an improvement over current treatment and prevention standards is warranted. Current therapeutic strategies have pri- marily focused on the administration of trimethoprim-sulfamethoxazole, which is effective at disease prevention. However, current treatments are inadequate for treatment of PCP and prevention of PCP-related death, as evidenced by consistently high mortality rates for those hospitalized with PCP. There are no vaccines in clinical trials for the prevention of PCP, and significant obstacles exist that have slowed development, including host range specificity, and the inability to culture Pneumocystis spp. in vitro. In this review, we overview the immune response to Pneumocystis spp., and discuss current progress on novel vaccines and therapies currently in the preclinical and clinical pipeline.
    [Show full text]
  • Mucormycosis of the Central Nervous System
    Journal of Fungi Review Mucormycosis of the Central Nervous System 1 1,2, , 3, , Amanda Chikley , Ronen Ben-Ami * y and Dimitrios P Kontoyiannis * y 1 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 64239, Israel 3 Department of Infectious Diseases, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA * Correspondence: [email protected] (R.B.-A.); [email protected] (D.P.K.) These authors contribute equally to this paper. y Received: 6 June 2019; Accepted: 7 July 2019; Published: 8 July 2019 Abstract: Mucormycosis involves the central nervous system by direct extension from infected paranasal sinuses or hematogenous dissemination from the lungs. Incidence rates of this rare disease seem to be rising, with a shift from the rhino-orbital-cerebral syndrome typical of patients with diabetes mellitus and ketoacidosis, to disseminated disease in patients with hematological malignancies. We present our current understanding of the pathobiology, clinical features, and diagnostic and treatment strategies of cerebral mucormycosis. Despite advances in imaging and the availability of novel drugs, cerebral mucormycosis continues to be associated with high rates of death and disability. Emerging molecular diagnostics, advances in experimental systems and the establishment of large patient registries are key components of ongoing efforts to provide a timely diagnosis and effective treatment to patients with cerebral mucormycosis. Keywords: central nervous system; mucormycosis; Mucorales; zygomycosis 1. Introduction Mucormycosis is the second most frequent invasive mold disease after aspergillosis [1–3], with rising incidence reported in some countries [4–7].
    [Show full text]
  • GAFFI Fact Sheet Pneumocystis Pneumonia
    OLD VERSION GLOBAL ACTION FUNDGAL FOR INFECTIONS FUN GAFFI Fact Sheet Pneumocystis pneumonia GLOBAL ACTION FUNDGAL FOR INFECTIONS Pneumocystis pneumonia (PCP) is a life-threatening illness of largely FUN immunosuppressed patients such as those with HIV/AIDS. However, when diagnosed rapidly and treated, survival rates are high. The etiologic agent of PCP is DARKER AREAS AND SMALLER VERSION TEXT FIT WITHIN CIRCLE (ALSO TO BE USED AS MAIN Pneumocystis jirovecii, a human only fungus that has co-evolved with humans. Other LOGO IN THE FUTURE) mammals have their own Pneumocystis species. Person to person transmission occurs early in life as demonstrated by antibody formation in infancy and early childhood. Some individuals likely clear the fungus completely, while others become carriers of variable intensity. About 20% of adults are colonized but higher colonization rates occur in children and immunosuppressed adults; ethnicity and genetic associations with colonization are poorly understood. Co-occurrence of other respiratory infections may provide the means of transmission in most instances. Patients with Pneumocystis pneumonia (PCP) are highly infectious. Prophylaxis with oral cotrimoxazole is highly effective in preventing infection. Pneumocystis pneumonia The occurrence of fatal Pneumocystis pneumonia in homosexual men in the U.S. provided one of earliest signals of the impending AIDS epidemic in the 1980s. Profound immunosuppression, especially T cell depletion and dysfunction, is the primary risk group for PCP. Early in the AIDS epidemic, PCP was the AIDS-defining diagnosis in ~60% of individuals. This frequency has fallen in the western world, but infection is poorly documented in most low-income countries because of the lack of diagnostic capability.
    [Show full text]
  • HIV Awareness in the Workplace Online Nursing CE Course
    Online Continuing Education for Nurses Linking Learning to Performance INSIDE THIS COURSE HIV AIDS 7 UNIT: HIV AWARENESS COURSE OUTLINE ............................ 2 IN THE WORKPLACE CHAPTER 1: HIV AIDS DEFINED ...... 3 CHAPTER 2: WORKPLACE 7.0 Contact Hours PROTECTION ................................. 11 0.7 Continuing Education Units CHAPTER 3: PATIENT CARE AND RIGHTS ......................................... 14 Written by: Robert Dunham, RMA CHAPTER 4: TUBERCULOSIS ........... 21 Objectives REFERENCES ................................ 29 CE EXAM...................................... 31 After completing HIV Awareness in the EVALUATION ................................. 38 Workplace, you will be able to: 1. Define HIV/AIDS including origin, etiology and epidemiology of HIV. 2. Understand how HIV/AIDS is transmitted and effective methods of infection control and prevention. 3. Discuss contamination myths and practice safe workplace habits to minimize workplace exposure. 4. Identify legal/ethical issues and patient rights surrounding HIV/AIDS. 5. Support patients with HIV/AIDS by providing accurate information and counseling when necessary. 6. Identify tuberculosis and how it impacts immune compromised patients. 7. Understand how medical facilities are taking steps to prevent tuberculosis in the workplace. 8. Understand how the World Health Organization is helping HIV patients with tuberculosis around the world, and how it impacts new defensive medicine techniques. Robert Dunham, RMA www.corexcel.com Page 2 HIV Awareness in the Workplace COURSE OUTLINE I. Etiology and epidemiology of HIV 1. Etiology 2. Reported AIDS cases in the United States and Washington State 3. Risk populations/behaviors II. Transmission and infection control 1. Transmission of HIV 2. Infection Control Precautions 3. Factors affecting risk for transmission 4. Risks for transmission to health care worker III. Testing and counseling 1.
    [Show full text]
  • Opportunistic Infections Moorine Sekadde, Mbchb Heidi Schwarzwald, MD, MPH
    HIV Curriculum for the Health Professional Opportunistic Infections Moorine Sekadde, MBchB Heidi Schwarzwald, MD, MPH Objectives Overview 1. Define opportunistic infections (OIs) in people with Many people living with human immunodeficiency virus human immunodeficiency virus (HIV)/AIDS. (HIV)/AIDS acquire diseases that also affect otherwise 2. Describe primary prophylaxis to prevent OIs in healthy people. In such cases, HIV-infected patients people with HIV/AIDS. may have a more severe disease course than uninfected 3. Evaluate the clinical manifestations of bacterial, people or may develop symptoms that uninfected viral, parasitic, and fungal OIs in people with HIV/ people do not. However, HIV-infected people are also AIDS. susceptible to opportunistic infections (OIs), which 4. Describe the treatment for bacterial, viral, parasitic, are infections caused by organisms that in a healthy and fungal OIs in people with HIV/AIDS. host would not cause significant disease. This module 5. Review specific interventions that can decrease the discusses both types of infection. The most common OIs development of OIs in people with HIV/AIDS. vary with geographic location. This module will give a broad overview of the concepts of preventing OIs and Key Points will discuss the most commonly diagnosed diseases worldwide. The module will cover specific diseases, how to 1. An OI is caused by organisms that would not recognize them, and which medicines are recommended produce significant disease in a person with a well- to treat them. Treatment recommendations are based functioning immune system. on available information and research. Not every 2. People with HIV/AIDS are susceptible to OIs because recommendation will be feasible in every setting.
    [Show full text]
  • Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St
    Burden of serious fungal infections in Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St. James School of Medicine, Kralendjik, Bonaire (Dutch Caribbean). 1 LEADING WI The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K. INTERNATIONAL 2 FUNGAL The University Hospital of South Manchester, (*Corresponding Author) National Aspergillosis Centre (NAC) Manchester, U.K. EDUCATION Background and Rationale The incidence and prevalence of fungal infections in Jamaica is unknown. The first human case of Conidiobolus coronatus infection was discovered in Jamaica (Bras et al. 1965). Cases of histoplasmosis and eumycetoma are reported (Fincharn & DeCeulaer 1980, Nicholson et al., 2004; Fletcher et al, 2001). Tinea capitis is very frequent in children Chronic pulmonary (East-Innis et al., 2006), because of the population being aspergillosis with aspergilloma (in the left upper lobe) in a 53- predominantly of African ancestry. In a one year study of 665 HIV yr-old, HIV-negative Jamaican male, developing after one infected patients, 46% of whom had CD4 cell counts <200/uL, 23 had year of antitubercular treatment; his baseline IgG pneumocystis pneumonia and 3 had cryptococcal meningitis (Barrow titer was 741 mg/L (0-40). As a smoker, he also had moderate et al. 2010). We estimated the burden of fungal infections in Jamaica emphysema. from published literature and modelling. Table 1. Estimated burden of fungal disease in Jamaica Fungal None HIV Respiratory Cancer ICU Total Rate Methods condition /AIDS /Tx burden 100k We also extracted data from published papers on epidemiology and Oesophageal ? 2,100 - ? - 2,100 77 from the WHO STOP TB program and UNAIDS.
    [Show full text]
  • Pneumocystis Pneumonia Jang-Jih Lu,1,2 Chao-Hung Lee3*
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW ARTICLE Pneumocystis Pneumonia Jang-Jih Lu,1,2 Chao-Hung Lee3* Pneumocystis pneumonia (PcP) in humans is caused by Pneumocystis jirovecii, which has recently been reclassified as a fungus because its cell wall composition and nucleotide sequences are more similar to those of fungi. PcP occurs only in immunocompromised individuals such as those with AIDS. Despite the use of highly active antiretroviral therapy, PcP remains the leading opportunistic infection in AIDS patients. Based on nucleotide sequence variations in the internal transcribed spacer region of rRNA genes, more than 60 different types of P. jirovecii have been identified. Although type differences do not appear to correlate with the clinical characteristics of PcP, nucleotide sequence variations of the organism have been useful in epidemiologic studies. As a result, some recurrent infections are found to be due to re-infection with new types, and outbreaks due to the same types of P. jirovecii have been identified. Initial diagnosis of PcP is usually based on symptoms and chest radiography. A characteristic histopathologic feature is the presence of acellular eosinophilic exudates and organisms in the alveoli. Ultimate diagnosis of PcP is achieved by demonstration of the organism in induced sputum or bronchoalveolar lavage fluid by tinctorial staining or polymerase chain reaction (PCR). Among the many different PCR methods, the nested PCR that targets the large subunit mitochondrial rRNA gene is the most sensitive and specific. Combination of trimethoprim and sulfamethoxazole is the first choice of drugs for both treatment and prophylaxis of PcP.
    [Show full text]
  • The Relationship Between Pneumocystis Infection in Animal and Human Hosts, and Climatological and Environmental Air Pollution Factors: a Systematic Review
    UCSF UC San Francisco Previously Published Works Title The Relationship between Pneumocystis Infection in Animal and Human Hosts, and Climatological and Environmental Air Pollution Factors: A Systematic Review. Permalink https://escholarship.org/uc/item/4b34c3wh Journal OBM genetics, 2(4) ISSN 2577-5790 Authors Miller, Robert F Huang, Laurence Walzer, Peter D Publication Date 2018 DOI 10.21926/obm.genet.1804045 Peer reviewed eScholarship.org Powered by the California Digital Library University of California HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author OBM Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2019 February 25. Published in final edited form as: OBM Genet. 2018 ; 2(4): . doi:10.21926/obm.genet.1804045. The Relationship between Pneumocystis Infection in Animal and Human Hosts, and Climatological and Environmental Air Pollution Factors: A Systematic Review Robert F. Miller1,2,3,4,*, Laurence Huang5,6, and Peter D. Walzer7 1.Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London WC1E 6JB, UK 2.Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK 3.Bloomsbury Clinic, Mortimer Market Centre, Central & North West London NHS Foundation Trust, London WC1E 6JB, UK 4.HIV Services, Royal Free London NHS Foundation Trust, London NW3 2QG, UK 5.Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General
    [Show full text]
  • 26Ypv8xo9426.Pdf
    Originally published as: Ina Tammer, Kathrin Tintelnot, Rüdiger C. Braun-Dullaeus, Christian Mawrin, Cordula Scherlach, Dirk Schlüter, Wolfgang König, Infections due to Pseudallescheria/Scedosporium species in patients with advanced HIV disease — a diagnostic and therapeutic challenge, International Journal of Infectious Diseases, Volume 15, Issue 6, June 2011, Pages e422-e429, ISSN 1201-9712. DOI: 10.1016/j.ijid.2011.03.004 This is an author manuscript. The definitive version is available at: http://www.sciencedirect.com/ Infections due to Pseudallescheria/Scedosporium species in patients with advanced HIV disease — a diagnostic and therapeutic challenge Ina Tammera, Kathrin Tintelnotb, Rüdiger C. Braun-Dullaeusc, Christian Mawrind, Cordula Scherlache, Dirk Schlütera, Wolfgang Königa a Institute of Medical Microbiology, Otto-von-Guericke University, Leipziger Str. 44, 39 120 Magdeburg, Germany b Division of Mycology, Robert Koch Institute, Berlin, Germany c Internal Medicine, Department of Cardiology, Angiology, and Pneumology, Otto- von-Guericke University, Magdeburg, Germany d Institute of Neuropathology, Otto-von-Guericke University, Magdeburg, Germany e Institute of Neuroradiology, Otto-von-Guericke University, Magdeburg, Germany Summary Objectives: The aim of this study is to highlight the importance of infections caused by members of the genera Pseudallescheria/Scedosporium in HIV-positive patients. Methods: We describe a case of a fatal scedosporiosis in a treatment-naïve HIV patient and review all previously reported cases of pseudallescheriosis/scedosporiosis from a search of the PubMed and Deutsches Institut für Medizinische Dokumentation und Information (DIMDI) databases, applying the terms ‘Pseudallescheria’, ‘Scedosporium’, ‘Allescheria’, ‘Monosporium’, ‘Petriellidium’, ‘boydii’, ‘prolificans’, ‘inflatum’, cross-referenced with ‘HIV’ and ‘AIDS’. Results: Detection of Scedosporium and Pseudallescheria species has been reported in 22 HIV- positive patients.
    [Show full text]
  • Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery
    Journal of Fungi Review Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery Cecilia Li 1, Sophie Lev 1, Adolfo Saiardi 2, Desmarini Desmarini 1, Tania C. Sorrell 1,3,4 and Julianne T. Djordjevic 1,3,4,* 1 Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia; [email protected] (C.L.); [email protected] (S.L.); [email protected] (D.D.); [email protected] (T.C.S.) 2 Medical Research Council Laboratory for Molecular Cell Biology, University College London, London WC1E 6BT, UK; [email protected] 3 Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Westmead, NSW 2145, Australia 4 Westmead Hospital, Westmead, NSW 2145, Australia * Correspondence: [email protected]; Tel.: +61-2-8627-3420 Academic Editor: Maurizio Del Poeta Received: 22 July 2016; Accepted: 30 August 2016; Published: 6 September 2016 Abstract: Opportunistic fungi are a major cause of morbidity and mortality world-wide, particularly in immunocompromised individuals. Developing new treatments to combat invasive fungal disease is challenging given that fungal and mammalian host cells are eukaryotic, with similar organization and physiology. Even therapies targeting unique fungal cell features have limitations and drug resistance is emerging. New approaches to the development of antifungal drugs are therefore needed urgently. Cryptococcus neoformans, the commonest cause of fungal meningitis worldwide, is an accepted model for studying fungal pathogenicity and driving drug discovery. We recently characterized a phospholipase C (Plc1)-dependent pathway in C. neoformans comprising of sequentially-acting inositol polyphosphate kinases (IPK), which are involved in synthesizing inositol polyphosphates (IP).
    [Show full text]